FIELD: biotechnology.
SUBSTANCE: CD19-specific antibody in synergistic combination with bendamustine for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia is declared.
EFFECT: invention provides for synergistic antitumor activity of specific CD19 antibodies and of bendamustine that can be used for effective treatment of B-cell malignancies.
7 cl, 10 dwg, 10 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY WITH ANTI-CD19 ANTIBODY AND A PURINE ANALOG | 2012 |
|
RU2664462C9 |
| COMBINATION OF CD19 ANTIBODY WITH BCL-2 INHIBITOR AND ITS APPLICATION METHODS | 2017 |
|
RU2756405C2 |
| COMBINATION OF CD19 ANTIBODY AND BRUTON TYROSINE KINASE INHIBITOR AND THEIR APPLICATION | 2016 |
|
RU2756010C2 |
| COMBINATIONS AND USE THEREOF | 2016 |
|
RU2767063C2 |
| TREATMENT APPROACH DESIGNED TO TREAT WITH A COMBINATION OF ANTI-CD19 ANTIBODY AND VENETOCLAX | 2018 |
|
RU2802812C2 |
| FORMULATIONS BASED ON CD19 ANTIBODY | 2017 |
|
RU2748024C2 |
| OLIGONUCLEOTIDES OR THEIR FUNCTIONAL HOMOLOGUES, COMPOSITION CONTAINING THEM AND METHOD OF TREATING B-CELL TUMOUR | 2006 |
|
RU2413519C2 |
| USING ANTI-CD40-ANTIBODIES | 2008 |
|
RU2491095C2 |
| CD37-IMMUNOTHERAPEUTIC COMBINATION THERAPY AND USING IT | 2009 |
|
RU2526156C2 |
| COMBINATIONS AND THEIR APPLICATION | 2013 |
|
RU2650618C2 |
